EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC

Yuanyuan Wang, Haoyue Guo, Ruoshuang Han, Yuhan Wu, Taiping He, Meng Diao, Anwen Xiong, Fei Zhou, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou

Cellular Oncology · 2026

DOI: 10.1007/s13402-025-01152-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2026. Verfasst von Yuanyuan Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tongji University, Shanghai, 200092, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms, Acrylamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shanghai Innovative Collaboration Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsAcrylamidesAniline CompoundsAntibodies, BispecificReceptor, ErbB-3Proto-Oncogene Proteins c-metImmunoconjugatesHumansAnimalsPyrimidinesErbB ReceptorsIndolesCell Line, TumorAntibodies, Monoclonal, HumanizedMice, NudeXenograft Model Antitumor AssaysFemaleMiceBroadly Neutralizing Antibodies

Stichwörter der Autor:innen

Antibody drug conjugateDrug resistanceEpidermal growth factor receptorHER3Non-small cell lung cancer

Substanzen

AcrylamidesAniline CompoundsPyrimidinesErbB ReceptorsIndolesosimertinibAntibodies, BispecificReceptor, ErbB-3Antibodies, Monoclonal, HumanizedProto-Oncogene Proteins c-met

Autor:innen und Institutionen

  • School of Medicine, Tongji University, Shanghai, 200092, China.
  • Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
  • Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
  • Department of Oncology, The First Affiliated Hospital of Army Medical University, Chongqing, China.
  • Graduate School of Bengbu Medical University, Bengbu, China.
  • Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Förderung

  • Shanghai Innovative Collaboration Project

Zitieren

APA

Wang, Y., Guo, H., Han, R., Wu, Y., He, T., Diao, M., Xiong, A., Zhou, F., Cheng, L., Zhao, C., Li, X., & Zhou, C. (2026). A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular Oncology. https://doi.org/10.1007/s13402-025-01152-8

Vancouver

Wang Y, Guo H, Han R, Wu Y, He T, Diao M, et al. A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. Cellular Oncology. 2026. doi:10.1007/s13402-025-01152-8

BibTeX
@article{Wang2026,
  author = {Wang, Yuanyuan and Guo, Haoyue and Han, Ruoshuang and Wu, Yuhan and He, Taiping and Diao, Meng and Xiong, Anwen and Zhou, Fei and Cheng, Lei and Zhao, Chao and Li, Xuefei and Zhou, Caicun},
  title = {A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-025-01152-8}
}
Kostenlos starten →